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Abstract: Metastatic breast cancer has been defined as a systemic
disease. Although resection of pulmonary metastases is a common
treatment in other primary malignancies, the role of breast cancer
metastasectomy is more contentious. Solitary or fewer numbers of
pulmonary metastases and longer disease-free interval are, as in
other cancers where pulmonary metastasectomy is performed, sig-
nificant prognostic factors. For proven pulmonary metastases, the
level of evidence for a curative approach is low, but some patients
might benefit from a metastasectomy followed by an elective and
appropriate complementary oncological treatment.
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Breast cancer with an incidence of 20 to 25% in Europe is themost frequent malignant disease in women. In approxi-
mately 30%, the cancer recurs within 5 years, 36% of these
patients have local recurrences and 56% metastases.1 Approxi-
mately 3% of all women with breast cancer develop a solitary
pulmonary lesion detectable by chest x-ray of which 33 to 40%
will be breast metastases,2,3 whereas the remaining two thirds
will be others type of tumors, chiefly primary lung cancer. Early
identification of the tumor is critical for determining appropriate
treatment strategies. The literature search identified 103 articles.
Most could be excluded as containing no data to inform the
evidence base, after sifting by title and abstract (Figure 1).
EVIDENCE AVAILABLE FOR REVIEW
Staren et al.4 retrospectively analyzed a series of 5143
patients presenting with breast cancer from 1972 to 1990. They
found that 284 patients had pulmonary metastases, but only 63
had metastatic disease confined to the lung. Thirty-three patients
underwent resection, and 30 had nonsurgical treatment. Only 10
of those undergoing surgery did not receive adjuvant chemother-
apy. These authors claimed “a significant advantage” for the surgi-
cal group in 5-year survivals (36% versus 11%) andmean survivals
(58 months versus 34 months) notwithstanding the likely dissimi-
larities between the 33 patients operated on and those who contrib-
uted the comparative mortality data.
In the more recent article, Singletary et al.5 present the
results of eight retrospective studies that examined the sur-
vival outcomes in the patients with breast cancer with isolated
metastases to the lung treated with surgery with or without
postsurgical systemic therapy. Median survival times ranged
from 42 months to 79 months, with 5-year actuarial survival
rates ranging from 35 to 80% and 10-year actuarial survival
rates ranging from 8 to 60%.
An analysis was performed in 467 female patients from
International Registry of Lung Metastases (IRLM). The sur-
vival rates associated with complete resection of pulmonary
metastases are 38, 22, and 20% after 5, 10, and 15 years,
respectively. Median survival was 37 months. Incomplete
resections were associated with a 5-year survival of 18% with
median survival being 25 months. The difference in the
log-rank test was significant.6
Among 13,502 patients with breast cancer at the Mayo
Clinic, there were 60 patients (0.4%) with isolated pulmonary
metastases.3 Actuarial 5-year survival was 35.6% in those with
apparent complete resections and 42.1% with incomplete resec-
tions. This study did not address the factors of possible prog-
nostic significance. The authors could not demonstrate improved
survival after complete pulmonary resection of metastatic breast
carcinoma in this highly selected group of patients.
Generally in pulmonary metastasectomy, a long disease-free
interval (DFI) after treatment of primary tumor is a prognostic factor
associatedwith positive survival outcomes. In lungmetastases from
breast cancer with or without chemotherapy, this has been shown.
In complete resections and DFI of36 months, the analysis of this
factor shows a 5-, 10-, and 15-year survival of 45, 26, and 21%,
respectively. When DFI was 36 months, survival rates at same
times were 28, 16, and 16%, respectively (P 0.0001). In incom-
plete resections, patients with a DFI 36 months also have a more
favorable prognosis.5
Various perioperative variables were investigated ret-
rospectively in 41 patients by Chen et al.,7 after lung metas-
tasectomy from breast cancer, to confirm the role of metas-
tasectomy and to analyze the prognostic factors for overall
survival. These authors considered that pulmonary metasta-
sectomy in patients with previous breast cancer might be
justified when fewer than four pulmonary metastases were
present or there was a DFI of more than 3 years.
Adjuvant therapies are the norm in breast cancer, and
additional chemotherapy before, after, or before and after me-
tastasectomy is likely to have an effect making interpretation of
the effect of surgery difficult. In a study by Staren et al.,4 themean
survival time was 55 months in the group receiving surgery com-
pared with 33 months in the group receiving medical treatment
only. Murabito et al.8 reported a mean survival time of 79 months
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in patients receiving surgery versus 9 months in patient receiving
medical treatment. In the International Registry of LungMetastases
(ILRM), 5-year survival after complete resection and without fur-
ther therapy was 39%, with chemotherapy after resection 44%, and
with prior chemotherapy 20%.5
Welter et al.9 retrospectively analyzed the role of breast
cancer metastasectomy in 47 patients with histologically
proven pulmonary metastases from breast cancer. The main
prognostic factor was the estrogen receptor status, with a
5-year survival for receptor positive patients of 76 and 12.1%
for receptor negative ones.
DISCUSSION
The widely varying outcomes in the eight series summa-
rized by Singletary et al.5 exemplified by quoted 10-year sur-
vival ranging from 8 to 60% is clearly a problem in drawing firm
conclusions from these reports. This variation is more likely to
be attributable to the patients and their selection than to the
quality or effectiveness of the surgery they received.
Selection is extreme. Two articles provide a denomi-
nator3,4 and are summarized in Table 1. Few patients with
breast cancer have solitary isolated lung metastases, and only
some of them are operated on. When the denominator is
available, a similar number (approximately 1/200) have sur-
gery, and the outcomes are identical for the highly selected
patients with operated solitary lung metastasis.
In assessing the effectiveness of metastasectomy, it is
usual to compare the results for those in whom complete
resection was achieved and in those in whom it was not. In
the IRLM data,6 there was twice the 5-year survival (38%
versus 16%) and a longer median survival. The difference
(albeit not significant) was in the other direction in the Mayo
clinic report (36% versus 42%).
Other factors associated with longer survival are the
number of metastases and the interval since the initial pre-
sentation, the diagnosis or first resection, and the pulmonary
metastasectomy, rather loosely referred to as the DFI. These
apply in breast cancer data,5,7 but as with other cancers, it is
a general prognostic feature irrespective of metastasectomy.
Given that breast cancer is treated as a systemic disease
and chemotherapy is the norm, separating the effects of surgery
from chemotherapy is difficult. Similarly, estrogen receptor
status is a general factor in the prognosis of breast cancer. Welter
et al.9 concluded that the evidence for a curative approach is low
and that gains in life expectancy for patients with breast cancer
with pulmonary metastases are attributable to chemotherapy and
antihormone treatment.
CONCLUSION
Although resection of pulmonary metastases is a common
treatment in other primary malignancies, the role of breast
cancer metastasectomy is controversial. It should be noted that
the majority of solitary nodules in these patients are not breast
cancer metastases, so resection of solitary nodules in these
women who may otherwise have a good prognosis is appropriate
for diagnosis and guide management. The level of evidence for a
curative approach for resection of proven pulmonary metastases is
low, but the evidence does not preclude the possibility that some
patients might benefit from ametastasectomy preceded or followed
by appropriate oncological treatment.
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FIGURE 1. Search diagram.
TABLE 1. Two Publications in Which the Number of
Patients Undergoing Pulmonary Metastasectomy for Breast
Cancer is Presented Along with the Denominator from
Which They were Drawn
Publication Staren et al.4 Mcdonald et al.3
Era 1972–1990 1982–1992
Total patients 5143 13502
Pulmonary metastases 284 (5.5%)
Only pulmonary metastases 63 (1.2%)
Pulmonary metastasectomy 30 (0.6%) 60 (0.4%)
No other treatment
Five-year survival 36% 36%
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